Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BNTCBullishAnalyst Target Updateanalyst

Medium materiality5/10

Raymond James Starts Benitec BioPharma at Outperform

Oct 23, 2026, 8:35 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The target implies substantial upside, but this is a single analyst view and the signal alone does not establish the likelihood of reaching it.

AI summary

What happened, with direct paths to the underlying reporting

Raymond James initiated coverage of BNTC at Outperform with a $14 target, about 59% above the posted price of $8.82. This is a bullish analyst opinion, not a guarantee of performance.

Outperform initiation; $14 target vs. $8.82 posted price.

Key facts

01
Target: $14
02
Posted price: $8.82
03
Analyst firm: Raymond James
04
Analyst: Tiago Fauth

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.